<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Nevirapine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00238</strong>&#160; (APRD00705, DB08311)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A potent, non-nucleoside reverse transcriptase inhibitor (<span class="caps">NNRTI</span>) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (<span class="caps">HIV</span>-1) infection and <span class="caps">AIDS</span>. [PubChem] Structurally, nevirapine belongs to the dipyridodiazepinone chemical class.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00238/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00238/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00238.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00238.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00238.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00238.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00238.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00238">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>NEV</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>NVP</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Viramune</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Viramune XR</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anti-hiv-agents">Anti-HIV Agents</a></li>
<li><a href="/mesh/reverse-transcriptase-inhibitors">Reverse Transcriptase Inhibitors</a></li></ul></td></tr><tr><th>CAS number</th><td>129618-40-2</td></tr><tr><th>Weight</th><td>Average: 266.2979<br>Monoisotopic: 266.11676109</td></tr><tr><th>Chemical Formula</th><td>C<sub>15</sub>H<sub>14</sub>N<sub>4</sub>O</td></tr><tr><th>InChI Key</th><td>NQDJXKOVJZTUJA-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">2-cyclopropyl-7-methyl-2,4,9,15-tetraazatricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3,5,7,11,13-hexaen-10-one</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC1=C2NC(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Pyridines and Derivatives</td></tr><tr><th>Subclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Direct parent</th><td>Pyridines and Derivatives</td></tr><tr><th>Alternative parents</th><td>Tertiary Amines; Secondary Carboxylic Acid Amides; Polyamines; Carboxylic Acids</td></tr><tr><th>Substituents</th><td>carboxamide group; tertiary amine; secondary carboxylic acid amide; carboxylic acid derivative; polyamine; carboxylic acid; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the pyridines and derivatives. These are compounds containing a pyridine ring, which is a six-member aromatic heterocycle which consists of one nitrogen atom and five carbon atoms.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For use in combination with other antiretroviral drugs in the ongoing treatment of HIV-1 infection.</td></tr><tr><th>Pharmacodynamics</th><td>Nevirapine is a non-nucleoside reverse transcriptase inhibitor (nNRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). HIV-2 RT and eukaryotic DNA polymerases (such as human DNA polymerases alpha, beta, or sigma) are not inhibited by nevirapine. Nevirapine is, in general, only prescribed after the immune system has declined and infections have become evident. It is always taken with at least one other HIV medication such as Retrovir or Videx. The virus can develop resistance to nevirapine if the drug is taken alone, although even if used properly, nevirapine is effective for only a limited time.</td></tr><tr><th>Mechanism of action</th><td>Nevirapine binds directly to reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic site. The activity of nevirapine does not compete with template or nucleoside triphosphates.</td></tr><tr><th>Absorption</th><td>Nevirapine is readily absorbed (greater than 90%) after oral administration in healthy subjects and adults with HIV-1 infection. The absolute bioavailability in healthy adults following a single dose administration is 93 &#177; 9% (mean &#177; SD) for a 50 mg tablet and 91 &#177; 8% for an oral solution. Peak plasma nevirapine concentrations of 2 &#177; 0.4 mcg/mL (7.5 micromolar) were attained by 4 hours following a single 200 mg dose. Nevirapine tablets and suspension have been shown to be comparably bioavailable and interchangeable at doses up to 200 mg. When the oral tablet is given with a high-fat meal, the extent of absorption is compared to that of the fasted-state. </td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>1.21 &#177; 0.09 L/kg [apparent volume of distribution, healthy adults, IV] <br>
Nevirapine is capable of crossing the placenta and is found in breast milk.</li>
</ul></td></tr><tr><th>Protein binding</th><td>60% bound to plasma protein. </td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic. In vivo studies in humans and in vitro studies with human liver microsomes have shown that nevirapine is extensively biotransformed via cytochrome P450 3A4 metabolism to several hydroxylated metabolites.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Nevirapine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li>
<li><a href="/biodb/bio_entities/BE0002363" target="_blank">Cytochrome P450 2D6</a></li>
<li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0002362" target="_blank">Cytochrome P450 3A5</a></li></ul></td><td><a href="/metabolites/DBMET00074">12-Hydroxynevirapine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/74">Details</a></td></tr><tr><td>Nevirapine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0002362" target="_blank">Cytochrome P450 3A5</a></li></ul></td><td><a href="/metabolites/DBMET00075">2-Hydroxynevirapine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/75">Details</a></td></tr><tr><td>Nevirapine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002363" target="_blank">Cytochrome P450 2D6</a></li>
<li><a href="/biodb/bio_entities/BE0003549" target="_blank">Cytochrome P450 2B6</a></li>
<li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li></ul></td><td><a href="/metabolites/DBMET00076">8-Hydroxynevirapine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/76">Details</a></td></tr><tr><td>Nevirapine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003549" target="_blank">Cytochrome P450 2B6</a></li></ul></td><td><a href="/metabolites/DBMET00077">3-Hydroxynevirapine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/77">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00074">12-Hydroxynevirapine</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00669">12-hydroxynevirapine glucuronide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1056">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00074">12-Hydroxynevirapine</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0000133" target="_blank">Aldehyde dehydrogenase, mitochondrial</a></li></ul></td><td><a href="/metabolites/DBMET00727">4-carboxynevirapine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1057">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00075">2-Hydroxynevirapine</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00685">2-hydroxynevirapine glucuronide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1058">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00076">8-Hydroxynevirapine</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00779">8-hydroxynevirapine glucuronide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1059">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00077">3-Hydroxynevirapine</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00712">3-hydroxynevirapine glucuronide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1060">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Thus cytochrome P450 metabolism, glucuronide conjugation, and urinary excretion of glucuronidated metabolites represent the primary route of nevirapine biotransformation and elimination in humans. Only a small fraction (</td></tr><tr><th>Half life</th><td>45 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Symptoms of overdose include edema, erythema nodosum, fatigue, fever, headache, insomnia, nausea, pulmonaryinfiltrates, rash, vertigo, vomiting, and weight decrease. The most common adverse reaction is rash. </td></tr><tr><th>Affected organisms</th><td><ul><li>Human Immunodeficiency Virus</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Nevirapine Metabolism Pathway</td><td>Drug metabolism</td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9958</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9756</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.8867</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.5606</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6488</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8514</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7124</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.6179</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.8919</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.6413</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.6175</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8009</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9451</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7971</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8309</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.5443</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          AMES toxic 
        </td>
        <td>
            0.5952
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9383
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.964
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.6729 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9827
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8321
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Boehringer ingelheim pharmaceuticals inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.boehringer-ingelheim.com">Boehringer Ingelheim Ltd.</a></li>
<li>Dept Health Central Pharmacy</li>
<li>Kaiser Foundation Hospital</li>
<li>Lake Erie Medical and Surgical Supply</li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li><a href="http://www.roxane.com">Roxane Labs</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Suspension</td><td>Oral</td><td>50 mg/5 mL</td></tr><tr><td>Tablet</td><td>Oral</td><td>200 mg</td></tr><tr><td>Tablet, extended release</td><td>Oral</td><td>100 mg, 400 mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>Nevirapine may decrease the anticoagulant effect of acenocoumarol.</td></tr><tr><td><a href="/drugs/DB01125">Anisindione</a></td><td>Nevirapine may decrease the anticoagulant effect of anisindione.</td></tr><tr><td><a href="/drugs/DB01072">Atazanavir</a></td><td>Nevirapine, a strong CYP3A4 inducer, may decrease the serum concentration of atazanavir by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of atazanavir if nevirapine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01076">Atorvastatin</a></td><td>Nevirapine, a strong CYP3A4 inducer, may decrease the serum concentration of atorvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if nevirapine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00266">Dicoumarol</a></td><td>Nevirapine may decrease the anticoagulant effect of dicumarol.</td></tr><tr><td><a href="/drugs/DB08866">Estradiol valerate/Dienogest</a></td><td>Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  </td></tr><tr><td><a href="/drugs/DB06414">Etravirine</a></td><td>Nevirapine may cause a significant decrease in plasma levels of etravirine and a loss of efficacy. 
Combination of two NNRTIs has not been demonstrated to be of benefit to HIV therapy.</td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>Nevirapine, a strong CYP3A4 inducer, may decrease the serum concentration of ketoconazole by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of ketoconazole if nevirapine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00227">Lovastatin</a></td><td>The strong CYP3A4 inducer, nevirapine, may decrase the effect of lovastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of lovastatin if nevirapine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00333">Methadone</a></td><td>The antiretroviral agent decreases the effect of methadone</td></tr><tr><td><a href="/drugs/DB00220">Nelfinavir</a></td><td>Nevirapine may decrease the effect of nelfinavir.</td></tr><tr><td><a href="/drugs/DB01369">Quinupristin</a></td><td>This combination presents an increased risk of toxicity</td></tr><tr><td><a href="/drugs/DB01656">Roflumilast</a></td><td>Affects CYP3A4 metabolism, decreases level or effect of roflumilast. </td></tr><tr><td><a href="/drugs/DB01232">Saquinavir</a></td><td>Decreases the effect of saquinavir</td></tr><tr><td><a href="/drugs/DB00641">Simvastatin</a></td><td>The strong CYP3A4 inducer, nevirapine, may decrase the effect of simvastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of simvastatin if nevirapine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01323">St. John's Wort</a></td><td>St. John's Wort decreases nevirapine effect</td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Nevirapine may decrease the plasma concentration of Telithromycin. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB06287">Temsirolimus</a></td><td>Nevirapine may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.  	</td></tr><tr><td><a href="/drugs/DB00932">Tipranavir</a></td><td>Nevirapine, a CYP3A4 inducer, may decrease the serum concentration of Tipranavir, a CYP3A4 substrate. Monitor for changesin Tipranavir effect if Nevirapine is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00193">Tramadol</a></td><td>Nevirapine may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. </td></tr><tr><td><a href="/drugs/DB00656">Trazodone</a></td><td>The CYP3A4 inducer, Nevirapine, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Nevirapine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB05294">Vandetanib</a></td><td>Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.  </td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>Nevirapine may decrease the anticoagulant effect of warfarin by increasing metabolism of R-warfarin via CYP3A4.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol.</li>
<li>Take without regard to meals.</li></ul></td></tr></tbody></table>